---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-282613"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:45:05.018436+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q3 net loss $45.1M; cash $419M; NVD200 on track for Q1 2023 trial

## Summary
- Net loss of $45.1M ($0.42 per share) vs $60.4M ($0.98) in Q3 2021; R&D expenses fell to $34.1M from $49.4M.
- Cash, cash equivalents and marketable securities of $419M as of Sept 30, 2022; expected runway into Q2 2024.
- NVD200 combination antibody candidate progressing toward clinical trial start in Q1 2023; demonstrated potent in vitro neutralization against Omicron sublineages.
- David Hering named permanent CEO in July; Fred Driscoll appointed interim CFO and Christine Lindenboom to board in October.
- Entered Platform Transfer Agreement with Adimab and signed 9,600 sq ft lease in Newton, MA for expanded lab space.

## SEC filing metadata
- accession: 0001193125-22-282613
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312522282613/0001193125-22-282613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312522282613/d407741d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-282613
- JSON: https://secwatch.observer/filing/0001193125-22-282613.json
- Plain text: https://secwatch.observer/filing/0001193125-22-282613.txt

## Key facts
- Earnings Releases
  Invivyd, Inc. reported the third quarter ended September 30, 2022 results: net income $45.1 million, EPS $0.42 per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: $45.1 million
  - EPS: $0.42 per share
  - Result: reported results
  source text: Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312522282613/0001193125-22-282613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.